Tharimmune Announces Expanded Role as Super Validator on Canton Network
THARAdvances Digital Asset Treasury Strategy Through Contributions to Canton Network NEW YORK, Jan. 26, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's...
Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering
THARNEW YORK, Jan. 20, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ: THAR), the first publicly traded company to leverage Canton Coin to support the Canton Network's ability to digitize traditional financial markets, today announced the pricing of a $55 million registered offering....
Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl
THAR(NASDAQ:THAR) RED BANK, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs announced that management will be participating in three upcoming Fall conferences.
Tharimmune CEO Randy Milby To Resign; Sireesh Appajosyula Appointed As CEO Effective Immediately
THARTharimmune Q1 EPS $(0.99) Up From $(2.55) YoY
THARTharimmune Highlights Presentation Of Data On TH104 Metabolic Profile At Digestive Disease Week
THARTharimmune Says FDA Confirmed No Additional Trials Appear To Be Necessary Prior To A 505(b)(2) New Drug Application Submission
THARTharimmune Announces Preclinical Data For HS1940
THARTharimmune Expanded Its Product Pipeline With HS1940, A Dual-target Multispecific Biologic Engineered To Bind To Both Programmed Death-1 And Vascular Endothelial Growth Factor Receptors
THARWhat's Going On With Tharimmune Shares Monday?
THARTharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented clinical data at the 75th American Association for the Study of Liver Disease (AASLD) meeting. Here's what you need to know.
Tharimmune shares are trading higher after the company announced it will present at the 75th AASLD liver meeting.
THARTharimmune Announces Presentation At AASLD The Liver Meeting
THARWhy Tharimmune (THAR) Shares Are Moving
THARTharimmune shares are trading lower by 16.4% during Wednesday's session. The company announced a 1-for-15 reverse stock split.
Tharimmune Earlier Announced A 1-For-15 Reverse Stock Split, Will Trade On A Post-Split Basis When The Market Opens On May 28, 2024
THAR